Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
Dogwood Therapeutics partnered with PRIDCor to globally develop and commercialize its antiviral candidates IMC-1 and IMC-2, shifting future development and commercialization costs to the partner. Under the agreement, Dogwood is eligible for potential payments capped at $100 million, tiered royalties up to 15%, and 9% of future capital raised or milestone payments related to the assets.
Key figures
- Deal Value Usd
- 100000000
- Max royalty rate
- 15%
- Future capital raisings share
- 9%
- Future partnership payments share
- 9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.